JP2015513901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513901A5 JP2015513901A5 JP2015503230A JP2015503230A JP2015513901A5 JP 2015513901 A5 JP2015513901 A5 JP 2015513901A5 JP 2015503230 A JP2015503230 A JP 2015503230A JP 2015503230 A JP2015503230 A JP 2015503230A JP 2015513901 A5 JP2015513901 A5 JP 2015513901A5
- Authority
- JP
- Japan
- Prior art keywords
- raf
- cancer
- polypeptide
- inhibitor
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616999P | 2012-03-28 | 2012-03-28 | |
| US61/616,999 | 2012-03-28 | ||
| US201261708372P | 2012-10-01 | 2012-10-01 | |
| US61/708,372 | 2012-10-01 | ||
| PCT/US2013/029513 WO2013148100A1 (en) | 2012-03-28 | 2013-03-07 | C-raf mutants that confer resistance to raf inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018048824A Division JP6661685B2 (ja) | 2012-03-28 | 2018-03-16 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513901A JP2015513901A (ja) | 2015-05-18 |
| JP2015513901A5 true JP2015513901A5 (enExample) | 2016-04-21 |
| JP6348898B2 JP6348898B2 (ja) | 2018-06-27 |
Family
ID=47892065
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503230A Active JP6348898B2 (ja) | 2012-03-28 | 2013-03-07 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
| JP2018048824A Active JP6661685B2 (ja) | 2012-03-28 | 2018-03-16 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
| JP2020019636A Pending JP2020103291A (ja) | 2012-03-28 | 2020-02-07 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018048824A Active JP6661685B2 (ja) | 2012-03-28 | 2018-03-16 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
| JP2020019636A Pending JP2020103291A (ja) | 2012-03-28 | 2020-02-07 | Ｒａｆ阻害剤に対する耐性を付与するｃ−ｒａｆ突然変異体 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9629839B2 (enExample) |
| EP (3) | EP2831589B1 (enExample) |
| JP (3) | JP6348898B2 (enExample) |
| KR (1) | KR20140139510A (enExample) |
| CN (1) | CN104204806B (enExample) |
| AU (1) | AU2013240483B2 (enExample) |
| BR (1) | BR112014023496A2 (enExample) |
| CA (1) | CA2864169A1 (enExample) |
| EA (1) | EA028135B1 (enExample) |
| ES (3) | ES2790896T3 (enExample) |
| MX (1) | MX351945B (enExample) |
| PL (1) | PL2831589T3 (enExample) |
| PT (1) | PT2831589T (enExample) |
| TR (1) | TR201808010T4 (enExample) |
| WO (1) | WO2013148100A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014023496A2 (pt) * | 2012-03-28 | 2017-07-18 | Dana Farber Cancer Inst Inc | mutantes c-raf que conferem resistência a inibidores de raf |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| KR102537840B1 (ko) | 2018-07-13 | 2023-05-31 | 삼성전자 주식회사 | 서버 장치 및 다른 장치들의 위치 정보를 수집하는 방법 |
| WO2020163771A1 (en) * | 2019-02-08 | 2020-08-13 | Portage Glasgow Limited | Structure, manufacturing and uses of hoxd12-pde8a cell-penetrating peptides |
| US20230183810A1 (en) * | 2020-05-04 | 2023-06-15 | Dna-Seq, Inc. | Methods and systems for determination of an effective therapeutic regimen and drug discovery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618670A (en) * | 1988-08-26 | 1997-04-08 | The United States Of America As Represented By The Department Of Health & Human Services | Detection method for c-raf-1 genes |
| US20060234931A1 (en) * | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
| AU2004262369A1 (en) | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| CN101516376A (zh) | 2006-09-18 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | 用于治疗携带egfr突变的癌症的方法 |
| BRPI0717586A2 (pt) * | 2006-09-18 | 2013-10-29 | Boehringer Ingelheim Int | Método para tratar câncer apresentando mutações do egfr |
| EP2102362B1 (en) | 2006-11-16 | 2012-07-04 | Mount Sinai School of Medicine of New York University | Compositions and methods for detecting noonan syndrome |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| EP2545187B1 (en) * | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| BR112014023496A2 (pt) * | 2012-03-28 | 2017-07-18 | Dana Farber Cancer Inst Inc | mutantes c-raf que conferem resistência a inibidores de raf |
-
2013
- 2013-03-07 BR BR112014023496A patent/BR112014023496A2/pt not_active IP Right Cessation
- 2013-03-07 JP JP2015503230A patent/JP6348898B2/ja active Active
- 2013-03-07 WO PCT/US2013/029513 patent/WO2013148100A1/en not_active Ceased
- 2013-03-07 ES ES18153021T patent/ES2790896T3/es active Active
- 2013-03-07 KR KR1020147026716A patent/KR20140139510A/ko not_active Ceased
- 2013-03-07 MX MX2014011686A patent/MX351945B/es active IP Right Grant
- 2013-03-07 CA CA2864169A patent/CA2864169A1/en not_active Abandoned
- 2013-03-07 EA EA201491780A patent/EA028135B1/ru not_active IP Right Cessation
- 2013-03-07 EP EP13710263.8A patent/EP2831589B1/en active Active
- 2013-03-07 ES ES20159381T patent/ES2908078T3/es active Active
- 2013-03-07 AU AU2013240483A patent/AU2013240483B2/en not_active Ceased
- 2013-03-07 PT PT137102638T patent/PT2831589T/pt unknown
- 2013-03-07 TR TR2018/08010T patent/TR201808010T4/tr unknown
- 2013-03-07 PL PL13710263T patent/PL2831589T3/pl unknown
- 2013-03-07 EP EP20159381.1A patent/EP3693741B1/en active Active
- 2013-03-07 ES ES13710263.8T patent/ES2673070T3/es active Active
- 2013-03-07 US US14/387,735 patent/US9629839B2/en active Active
- 2013-03-07 EP EP18153021.3A patent/EP3333575B1/en active Active
- 2013-03-07 CN CN201380014747.6A patent/CN104204806B/zh active Active
-
2017
- 2017-03-29 US US15/472,934 patent/US20170204383A1/en not_active Abandoned
-
2018
- 2018-03-16 JP JP2018048824A patent/JP6661685B2/ja active Active
-
2019
- 2019-01-23 US US16/255,251 patent/US20190142830A1/en not_active Abandoned
-
2020
- 2020-02-07 JP JP2020019636A patent/JP2020103291A/ja active Pending
-
2021
- 2021-08-11 US US17/399,563 patent/US11788151B2/en active Active
-
2023
- 2023-09-11 US US18/464,360 patent/US12146196B2/en active Active
-
2024
- 2024-10-14 US US18/914,634 patent/US20250034652A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| Patel et al. | Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma | |
| Ferone et al. | Cells of origin of lung cancers: lessons from mouse studies | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| Rubino et al. | Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer | |
| Ali et al. | PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer | |
| JP2017513908A5 (enExample) | ||
| RU2017120287A (ru) | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 | |
| JP2015530080A5 (enExample) | ||
| JP2015509489A5 (enExample) | ||
| JP2017516458A5 (enExample) | ||
| Cucurull et al. | Targeting KRAS in lung cancer beyond KRAS G12C inhibitors: the immune regulatory role of KRAS and novel therapeutic strategies | |
| JP2016513456A5 (enExample) | ||
| Kato et al. | Lactate dehydrogenase and hemolysis in sickle cell disease | |
| EA201401353A1 (ru) | Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк) | |
| Draenert et al. | The prevalence of tooth hypersensitivity following periodontal therapy with special reference to root scaling. A systematic review of the literature. | |
| JP2019512020A5 (enExample) | ||
| ES2813877T3 (es) | Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos | |
| Mangana et al. | Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof | |
| JP2014531020A5 (enExample) | ||
| Algazi et al. | Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma | |
| Tan et al. | LncRNA SBF2-AS1: A budding star in various cancers | |
| Jing et al. | Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target |